DEA Reviews Continuus Pharmaceuticals' Application for Bulk Drug Manufacturing
Published Date: 8/21/2025
Notice
Summary
Continuus Pharmaceuticals wants to become an official big-time maker of certain controlled drugs. This means they’ll be allowed to produce these substances in large amounts, which could impact medicine supply and safety. If approved, this change will help keep important medicines available while following strict rules.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17592, Thomas Earley, D.D.S.; Decision and Order
2026-17594, Atlantic Treatment Center, LLC; Decision and Order
The DEA has officially shut down Atlantic Treatment Center in Florida because it lost its state license and federal certification to treat substance use disorders. This means the center can no longer operate legally, protecting public health and safety. The center’s DEA registration expired on June 30, 2026, and this decision finalizes the revocation, making it clear no more services can be offered.
2026-17589, Leila Kump, M.D.; Decision and Order
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
Previous / Next Documents
Previous: 2025-16006, Importer of Controlled Substances Application: Vici Health Sciences, LLC
Vici Health Sciences, LLC wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs that need special handling and rules. If approved, this could affect companies and regulators keeping track of these substances, with no immediate cost changes announced.
Next: 2025-16009, Agency Information Collection Activities; Comment Request on Form 4506, 4506T-EZ and 4506T-EZ (SP)
The IRS wants your thoughts on updating Forms 4506, 4506T-EZ, and 4506T-EZ (SP), which people use to request tax transcripts. If you’ve ever needed these forms, this affects you! The IRS aims to make the forms easier and quicker to use, so expect smoother paperwork soon. They’re asking for comments before making changes, so now’s the time to speak up!